LOGIN  |  REGISTER
Chimerix
Assertio

Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference

May 13, 2024 | Last Trade: US$19.23 0.04 -0.21

PRINCETON, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the 2024 Bank of America Healthcare conference on Tuesday, May 14, 2024 at 4:40pm ET.

A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at http://investor.integralife.com/events-and-presentations.

About Integra LifeSciences

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands that include Acclarent®, AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit www.integralife.com .

Investor Relations:
Chris Ward
(609) 772-7736
This email address is being protected from spambots. You need JavaScript enabled to view it.   

Media Contact:
Laurene Isip
(609) 208-8121
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB